GlassScriptPhysician profile
Allison M Ladner
NPI 1669922886
$872.89
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $873.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $373.59 | 2021 | |
| Renovia INC | $126.87 | 2021 | |
| Therapeuticsmd, INC. | $60.88 | 2021 | |
| Aspira Women'S Health INC | $46.57 | 2021 | |
| Merck Sharp & Dohme LLC | $41.08 | 2021 | |
| Avion Pharmaceuticals | $38.85 | 2021 | |
| Mylan Pharmaceuticals INC. | $36.72 | 2021 | |
| Organon LLC | $32.35 | 2021 | |
| Evofem Biosciences, INC. | $29.65 | 2021 | |
| Agile Therapeutics, INC. | $28.65 | 2021 | |
| Mayne Pharma Commercial LLC | $23.45 | 2021 | |
| Exeltis, USA INC. | $17.96 | 2021 | |
| Myovant Sciences INC. | $16.27 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Ladner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.